[xoo_el_inline_form active="login"]

Investment

Line

Armed-T Product Pipeline

CytoArm owns >50 Armed T product rights for cancers and autoimmune diseases
Pipeline

Investment01
1st Product: Armed T cell (CTA-02) for EGFR mutated colorectal cancer

Armed-T Product Pipeline

Licensing CTA-02 to big pharma after completion of 1st patient treatment
Pipeline

CytoArm Owns Complete Armed-T Patents

Investment03

Cooperation Teams